SAN ANTONIO--(BUSINESS WIRE)--ViroXis Corporation today announced that the US Food and Drug Administration (FDA) granted approval for the Company’s investigational new drug (IND) application and planned clinical development of a drug substance derived from East Indian Sandalwood oil (EISO) for the topical treatment of Human Papilloma Virus (HPV), common warts of the skin. ViroXis’ EISO-derived product is being developed in accordance with the FDA’s 2004 Guidance for Development of Botanical Drugs.
